TAK - Takeda Pharmaceutical Company Limited

NYSE - Nasdaq Real-time price. Currency in USD
16.05
-0.06 (-0.34%)
As of 03:04PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close16.10
Open16.12
Bid16.05 x 4000
Ask16.06 x 3200
Day's range16.02 - 16.16
52-week range12.28 - 17.15
Volume1,610,758
Avg. volume2,348,109
Market cap50.033B
Beta (5Y monthly)0.68
PE ratio (TTM)22.28
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield0.66 (4.10%)
Ex-dividend date29 Sept 2022
1y target estN/A
  • Zacks

    Reasons to Add Puma (PBYI) Stock to Your Portfolio Right Now

    Puma Biotechnology (PBYI), a top-ranked stock, has a promising development candidate, alisertib. Its only marketed product, Nerlynx (neratinib), is witnessing improving demand trends in the United States.

  • Zacks

    Should Value Investors Buy Takeda Pharmaceutical Co. (TAK) Stock?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Zacks

    Are Investors Undervaluing Takeda Pharmaceutical Co. (TAK) Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Motley Fool

    2 Incredibly Cheap High-Yield Dividend Stocks to Buy Now

    High-yield dividend stocks can be a great way to protect your portfolio from market volatility. Read on to find out more about these two high-yield dividend stocks. Ford, and most of its contemporaries, took a big step backward last year over concerns about the impact of rising interest rates on demand for new vehicles.

  • Zacks

    Is Grifols (GRFS) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Motley Fool

    Is This the Telltale Sign to Sell Novavax Stock?

    Unfortunately, Novavax (NASDAQ: NVAX) hasn't had great timing. The company was late to the party in winning authorizations for its COVID-19 vaccine, Nuvaxovid. If you only looked at Novavax's press releases, you wouldn't know about some recent bad news for the company.

  • Motley Fool

    Why Puma Biotechnology's Shares Jumped 20% on Monday

    The biopharmaceutical company specializes in cancer therapies. Its stock got a boost on Monday when a Takeda Pharmaceutical (NYSE: TAK) candidate, ponatinib, hit its primary goal in a phase 3 clinical trial as a treatment for Philadelphia chromosome-positive acute lymphoblastic leukemia. The blood cancer therapy works by slowing the activity of BCR-ABL1, a gene sequence found in an abnormal chromosome 22, often seen in people with certain types of leukemia.

  • Motley Fool

    2 Beaten-Down Dividend Stocks That Haven't Been This Cheap In More Than a Decade

    Are these a couple of rare opportunities that investors shouldn't pass up, or are the price drops valid because of significant concerns that should keep you away from these companies? Takeda is a Japan-based healthcare company that makes vaccines and pharmaceutical products.

  • Motley Fool

    3 High-Yielding Dividend Stocks Near Their 52-Week Lows

    One happy consequence of a bear market is that dividend yields rise as stock prices fall. Three beaten-up stocks trading near their 52-week lows that could be especially attractive right now include Takeda Pharmaceuticals (NYSE: TAK), Duke Energy (NYSE: DUK), and Home Depot (NYSE: HD). Japanese drugmaker Takeda Pharmaceuticals is a leading healthcare company that makes vaccines and products addressing multiple therapeutic areas, including cancer, rare diseases, gastroenterology, and hematology.

  • Zacks

    TAK vs. ZTS: Which Stock Should Value Investors Buy Now?

    TAK vs. ZTS: Which Stock Is the Better Value Option?

  • Zacks

    Puma Biotech (PBYI) Inks Agreement for Takeda's Alisertib

    Puma Biotechnology (PBYI) inks license agreement with Japan's Takeda Pharmaceuticals, gaining worldwide development and commercialization rights to the latter's cancer treatment alisertib.

  • Zacks

    Is Takeda Pharmaceutical Co. (TAK) Stock Undervalued Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Motley Fool

    Got $5,000? These 2 Dividend Stocks Haven't Been This Cheap in Years

    When dividend stocks dip in price and go on sale, they can create buying opportunities for long-term investors. Takeda Pharmaceuticals (NYSE: TAK) and Verizon Communications (NYSE: VZ) are both at multi-year lows, and here's why they could be attractive options for a $5,000 investment. Takeda Pharmaceuticals is one of the largest drug companies in the world.

  • Zacks

    TAK or ZTS: Which Is the Better Value Stock Right Now?

    TAK vs. ZTS: Which Stock Is the Better Value Option?

  • Zacks

    Is Takeda Pharmaceutical Co. (TAK) a Great Value Stock Right Now?

    Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

  • Zacks

    TAK vs. ZTS: Which Stock Is the Better Value Option?

    TAK vs. ZTS: Which Stock Is the Better Value Option?

  • Zacks

    Wall Street Analysts See a 26% Upside in Takeda Pharmaceutical Co. (TAK): Can the Stock Really Move This High?

    The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

  • Motley Fool

    What's Winning in 2022? 3 Stocks That Are Doing Fine

    It's been an ugly year in the stock market in 2022, and most investors are deep in the red. For instance, Immunocore (NASDAQ: IMCR) investors just had a U.S. Food and Drug Administration (FDA) approval, and that stock has shot higher with a 30% gain this year. Will Axsome Therapeutics (NASDAQ: AXSM) be the next stock to pop?

  • Motley Fool

    2 Best High-Yield Dividend Stocks to Buy Right Now

    Dividend stocks are a great way to navigate volatile markets. History has shown that companies with solid balance sheets, diverse revenue streams, and a rich tradition of increasing annual distributions to shareholders tend to be the best vehicles when it comes to staving off the negative effects of economic downturns. With this insight in mind, my top two dividend stocks to buy right now are Icahn Enterprises (NASDAQ: IEP) and Takeda Pharmaceutical Company (NYSE: TAK).

  • Motley Fool

    Want Loads of Passive Income? Avoid These 3 (Very) Tempting Mistakes

    Dividend stocks are just as prone as other stocks to underperforming the market and doing pretty much everything except what you want them to do -- increase and pay out. The catch is that some of the worst dividend investing mistakes are disguised as being juicy opportunities. Let's go over three of the most tempting and most destructive foibles so that you'll be protected against them when you're figuring out which passive income stocks are worth your money.

  • Yahoo Finance

    FDA advisory committee recommends Novavax vaccine for use in adults

    FDA votes to recommend use of Novavax COVID-19 vaccine in adults